#	Pagina
attuale pagina	/open-h2020/projects/217097/index.html
-1	/open-h2020/projects/200491/index.html
-2	/open-h2020/projects/212650/index.html
-3	/open-h2020/per-topic/sequester/list/index.html

Opendata, web and dolomites

PICARD

Disruptive GPCR Lead Discovery Platform Delivering New and Safer Therapeutics

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

PICARD project word cloud

Explore the words cloud of the PICARD project. It provides you a very rough idea of what is the project "PICARD" about.

implicated gt fail company fast mechanisms identification therapeutics signalling biotech 375 successfully trials drug time assays commercialization detection costly price safety services compounds variety profiles paul fee paying inefficiencies reaching scherrer milestone class gpcr protein service leaving society designed payments 2b drugs inflates biology platform uuml stages discovery earlier 45 80 companies disease clinical gpcrs pharmacologically candidates lies risks cover upfront quality eth trial play custom screening activation efficient selective central outsourcing investment coupled off functional interax combination novelty patients revenue biological receptors stream human roi estimate spin z vital reducing lowering 5000 pharmaceutical diseases efficacy swiss break picard fte market nature

Project "PICARD" data sheet

The following table provides information about the project.

Coordinator	INTERAX BIOTECH AG Organization address address: PARK INNOVAARE city: VILLINGEN postcode: 5234 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Switzerland [CH]
Project website	http://www.interaxbiotech.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-08-01 to 2018-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INTERAX BIOTECH AG INTERAX BIOTECH AG Organization address address: PARK INNOVAARE city: VILLINGEN postcode: 5234 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (VILLINGEN)	coordinator	50˙000.00

Map

Project objective

InterAx Biotech, a Swiss company and spin-off from the ETH Zürich and the Paul Scherrer Institute has built PICARD, a unique drug discovery platform for the identification of drug candidates with improved efficacy and reduced side effects for the largest class of human receptors: The G-Protein Coupled Receptors (GPCRs). These receptors play a central role in many vital biological processes and they are implicated in a large variety of human diseases. Due to their complex nature and mechanisms that lead to the disease state, only 60 out of 375 pharmacologically relevant GPCRs have been successfully targeted by drugs, leaving >80% GPCRs without therapeutics. Bringing a drug to the market requires an investment of up to €2.2B; out of 5000 compounds only 5 will make it to the clinical trial phase and 9 out of 10 compounds fail during costly clinical trials. This inflates the price of the drugs that reach the patients, making the society paying for inefficiencies of pharmaceutical R&D. PICARD will enable better and earlier detection of safety and efficacy profiles of GPCR-targeting drugs by increasing quality and reducing costs and time-to-market of new therapeutics. The novelty of our discovery platform lies on the combination of our screening to find novel compounds, signalling Assays that cover the most common GPCR activation aspects and our Systems Biology approach leading to highly efficient and fast delivery of functional-selective compounds. We offer custom-designed PICARD services to pharmaceutical and biotech companies that are outsourcing key stages of their drug discovery process lowering risks and greatly reducing R&D costs. The revenue stream is generated both from fee per service and from long-term drug discovery partnerships with upfront and milestone payments. We estimate reaching break-even 2 years after commercialization with 45 FTE and achieving a ROI of 4.5.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICARD" are provided by the European Opendata Portal: CORDIS opendata.